Latest News

Transvaginal polypropylene mesh implants for the treatment of pelvic floor disorders have gained significant media coverage over the last decade, catalyzed by the public health notice issued by the United States Food and Drug Administration (FDA) in 2008 and the subsequent update in 2011 regarding the adverse events related to the urogynecology use of surgical […]

Ashish Kamat: Welcome everybody to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from Houston, at MD Anderson Cancer Center. And I’m joined today by Dr. Shilpa Gupta, who’s a medical oncologist at the Cleveland Clinic, and a true expert in everything to do with bladder cancer. Today, she’s going to join us and present […]

FDA Approval Includes Companion Diagnostic Claims for Rubraca® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer FoundationOne Liquid CDx Analyzes More Than 300 Genes and Genomic Signatures to Help Inform Treatment Decisions for all Solid Tumor Cancers San Francisco, CA (UroToday.com) — Foundation Medicine, […]

{{header-clinical-trials-navigation}} A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) Condition: Urothelial Carcinoma, Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Cancer, Transitional Cell Carcinoma Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04527991 Sponsor: Immunomedics, Inc. Phase: Phase […]

To determine the patient-perceived effectiveness and tolerability of mirabegron compared to solifenacin in a multiple sclerosis (MS) population with overactive bladder (OAB) symptoms. MS patients with OAB symptoms who were not on medication for their urinary symptoms at enrollment were prospectively recruited.

To compare the postoperative continence and clinical outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy (RS-RALP) with non-RS RALP for patients with prostate cancer. We searched PUBMED, EMBASE and the Cochrane Central Register from 1999 to 2019 for studies comparing RS-RALP to non-RS RALP for the treatment of prostate cancer.

To demonstrate two distinct methods for adopting the single-port robotic surgery system (SP) for robotic-assisted radical prostatectomy (RALP) by two-experienced robotic surgeons (JWD and RA) and evaluate early outcomes with each strategy.

Upper tract urothelial carcinoma with pure non-urothelial histology is an exception but variants are present in ~ 25% of cases. Primary upper urinary tract signet -ring cell carcinoma is extremely rare.

Although testicular cancer (TC) is the most common tumor in young men in Western countries, there is no official cancer detection/screening program for young men in Germany. The most important TC detection tool is self-examination of the testis.

The aim of the study was to investigate associations between computed tomography (CT) imaging characteristics, DNA methylation subtyping, and overall survival in renal cell carcinomas. Survival curves were calculated using the Kaplan-Meier analysis.